Should I buy or sell Kiora Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPRX shares. View KPRX analyst ratings or view top-rated stocks .

What is Kiora Pharmaceuticals' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Kiora Pharmaceuticals' stock. Their KPRX share price targets range from $7.00 to $119.00. On average, they expect the company's stock price to reach $46.00 in the next year. This suggests a possible upside of 8,418.5% from the stock's current price. View analysts price targets for KPRX or view top-rated stocks among Wall Street analysts .

How have KPRX shares performed in 2023?

Kiora Pharmaceuticals' stock was trading at $3.43 at the beginning of 2023. Since then, KPRX stock has decreased by 84.3% and is now trading at $0.54. View the best growth stocks for 2023 here .

Are investors shorting Kiora Pharmaceuticals?

Kiora Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 539,900 shares, an increase of 67.3% from the October 31st total of 322,700 shares. Based on an average trading volume of 116,000 shares, the short-interest ratio is currently 4.7 days. Approximately 7.8% of the shares of the stock are sold short. View Kiora Pharmaceuticals' Short Interest .

When is Kiora Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our KPRX earnings forecast .

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($11.60) EPS for the quarter, beating analysts' consensus estimates of ($13.48) by $1.88.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals's stock reverse split on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Kiora Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KPRX)

$0.54

+0.02 (+3.85%)

(As of 11/29/2023 ET)

Compare

Today's Range: $0.52
▼
$0.55
50-Day Range: $0.51
▼
$0.67
52-Week Range: $0.46
▼
$8.52

Volume: 38,291 shs
Average Volume: 581,324 shs
Market Capitalization: $4.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.00

Kiora Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 8,418.5% Upside
$46.00 Price Target
Short Interest: Bearish
7.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.44
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.66) to ($0.88) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Kiora Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.00, Kiora Pharmaceuticals has a forecasted upside of 8,418.5% from its current price of $0.54.
Amount of Analyst Coverage
Kiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.75% of the float of Kiora Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Kiora Pharmaceuticals has recently increased by 67.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kiora Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kiora Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KPRX.

1.9

News and Social Media Coverage

News Sentiment
Kiora Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Kiora Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for KPRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 13.92% of the stock of Kiora Pharmaceuticals is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kiora Pharmaceuticals are expected to grow in the coming year, from ($2.66) to ($0.88) per share.
Price to Book Value per Share Ratio
Kiora Pharmaceuticals has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kiora Pharmaceuticals Stock (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

KPRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KPRX Stock News Headlines

November 17, 2023 | finance.yahoo.com

Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301

November 11, 2023 | benzinga.com

Kiora Pharmaceuticals Stock (NASDAQ:KPRX) Earnings Dates and Earning Calls

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 9, 2023 | msn.com

Kiora Pharmaceuticals reports Q3 results

November 9, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

November 8, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)

November 6, 2023 | markets.businessinsider.com

Analyst Expectations for Kiora Pharmaceuticals's Future

November 4, 2023 | finance.yahoo.com

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

October 16, 2023 | finance.yahoo.com

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

October 3, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

September 21, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

September 18, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

September 14, 2023 | finance.yahoo.com

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

September 1, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

August 29, 2023 | finance.yahoo.com

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

August 24, 2023 | finance.yahoo.com

Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis

August 23, 2023 | marketwatch.com

Kiora Pharmaceuticals Shares Up 18% on Patents Covering Ocular Delivery of Molecules

August 23, 2023 | markets.businessinsider.com

Why Is Kiora Pharmaceuticals (KPRX) Stock Up 11% Today?

August 23, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

August 22, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

August 16, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

August 8, 2023 | finance.yahoo.com

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

August 3, 2023 | finance.yahoo.com

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

August 1, 2023 | finance.yahoo.com

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

July 21, 2023 | investorplace.com

Why Is Kiora Pharmaceuticals (KPRX) Stock Down 7% Today?

July 5, 2023 | finanznachrichten.de

Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease

See More Headlines

Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/28/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KPRX
CUSIP: N/A
CIK: 1372514
Web: eyegatepharma.com
Phone: (781) 788-9043
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $46.00
High Stock Price Target: $119.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +8,418.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,580,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -117.71%
Return on Assets: -71.82%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.32
Quick Ratio: 3.32

Sales & Book Value

Annual Sales: $10,000.00
Price / Sales: 415.26
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.05 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 7,690,000
Free Float: 7,617,000
Market Cap: $4.15 million
Optionable: Not Optionable
Beta: -0.24

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Brian M. Strem Ph.D. (Age 43)
President, CEO & Director
Comp: $464.93k
Ms. Melissa Tosca CPA (Age 43)
Executive Vice President of Finance
Comp: $282.28k
Dr. Eric J. Daniels M.B.A. (Age 50)
M.D., Chief Development Officer
Comp: $371.47k
Dr. Stefan Sperl Ph.D.
Executive Vice President of CMC & Operations

Key Competitors

View All Competitors

KPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiora Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPRX shares.
View KPRX analyst ratings or view top-rated stocks.
What is Kiora Pharmaceuticals' stock price target for 2024?: 3 equities research analysts have issued 12-month price objectives for Kiora Pharmaceuticals' stock. Their KPRX share price targets range from $7.00 to $119.00. On average, they expect the company's stock price to reach $46.00 in the next year. This suggests a possible upside of 8,418.5% from the stock's current price.
View analysts price targets for KPRX or view top-rated stocks among Wall Street analysts.
How have KPRX shares performed in 2023?: Kiora Pharmaceuticals' stock was trading at $3.43 at the beginning of 2023. Since then, KPRX stock has decreased by 84.3% and is now trading at $0.54.
View the best growth stocks for 2023 here.
Are investors shorting Kiora Pharmaceuticals?: Kiora Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 539,900 shares, an increase of 67.3% from the October 31st total of 322,700 shares. Based on an average trading volume of 116,000 shares, the short-interest ratio is currently 4.7 days. Approximately 7.8% of the shares of the stock are sold short.
View Kiora Pharmaceuticals' Short Interest.

When is Kiora Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our KPRX earnings forecast.
How were Kiora Pharmaceuticals' earnings last quarter?: Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($11.60) EPS for the quarter, beating analysts' consensus estimates of ($13.48) by $1.88.
When did Kiora Pharmaceuticals' stock split?: Kiora Pharmaceuticals's stock reverse split on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of Kiora Pharmaceuticals?: Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KPRX) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial